Atrium Therapeutics, Inc.
RNA
$10.51
-$0.84-7.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Net Income | -20.19M | -16.63M | -29.14M | -12.88M | |
| Total Depreciation and Amortization | 343.00K | 151.00K | 122.00K | 79.00K | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 1.40M | 13.05M | 4.00M | 1.78M | |
| Change in Net Operating Assets | 14.52M | -27.72M | 5.76M | -886.00K | |
| Cash from Operations | -3.93M | -31.14M | -19.25M | -11.91M | |
| Capital Expenditure | -36.00K | -2.10M | -879.00K | -266.00K | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -191.55M | -- | -- | -- | |
| Cash from Investing | -191.59M | -2.10M | -879.00K | -266.00K | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -- | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 0.00 | 301.51M | 20.13M | 12.17M | |
| Cash from Financing | 0.00 | 301.51M | 20.13M | 12.17M | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -195.51M | 268.26M | -- | -- | |